Abstract
Background: Although significant progress has been made in immune checkpoint inhibitor (ICI) treatment of advanced squamous cell carcinoma (SqCC), most patients still experience acquired drug resistance. Methods: We used a dendritic cell-based neoantigen vaccine combined with ICIs to treat advanced SqCC in a PD-1 blockade-resistant patient. Results: The follow-up of this patient after 12 months revealed significant tumor regression. We also identified a new JAK1 ICI-resistant mutation that could become a potential universal neoantigen target for tumor vaccines. Conclusion: Individualized management of advanced SqCC through a combined neoantigen vaccine and ICI administration could yield beneficial clinical outcomes. Vaccines targeting anti-PD-1-resistant JAK1 mutations might be of particular benefit to a specific group of solid tumor patients.
Plain language summary
Immunotherapy based on immune checkpoint inhibitors (ICIs) is very effective in lung cancer treatment. However, many patients with initial response will later develop resistance. There are not many treatment options for patients with drug resistance. Herein, we report a patient with lung cancer who became resistant to ICI, treated with personalized vaccine plus ICI. Based on the patient's own somatic mutational profile, personalized neoantigen vaccines were designed and manufactured unique to the patient. Our report indicated that personalized vaccine plus ICI was safe and might overcome ICI resistance. A new ICI resistance mutation on JAK1 as a potential universal neoantigen target for off-the-shelf vaccine was found, which is promising for the effective treatment of a specific group of patients with JAK1 mutations.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
Reference
- 1. . Mechanisms of anti-PDL1 resistance. Nat. Rev. Urol. 15, 201 (2018). • Pointed out that immune checkpoint inhibitor (ICI) treatment can result in durable responses in patients with tumors, but many tumors are resistant to this therapy, and a combination of ICI and neoantigen vaccine might be an option for overcoming resistance to ICI.
- 2. . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021). • Revealed advances in neoantigen vaccine in clinical trials, pointed out that a combination of ICI and neoantigen vaccine might be an option to improve the efficacy of immunotherapy.
- 3. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184), 641–645 (2014).
- 4. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348(6236), 803–808 (2015).
- 5. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375(23), 2255–2262 (2016).
- 6. An immunogenic personal neoantigen vaccine for patients with melanoma [published correction appears in Nature. 2018 Mar 14;555(7696):402]. Nature 547(7662), 217–221 (2017).
- 7. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547(7662), 222–226 (2017). • Is an important literature in application of personalized neoantigen vaccine therapy in a clinical trial, proved that a combination of ICI and neoantigen vaccine might be an option to improve the efficacy of immunotherapy and MHC class II neoantigens were important for target selection.
- 8. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738), 234–239 (2019).
- 9. . Complementing the cancer-immunity cycle. Front. Immunol. 10, 774 (2019).
- 10. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification. BMC Bioinformatics 21(1), 532 (2020). •• Cited as detailed bioinformatic algorithm reference to select neoantigens. 10 and 1 neoantigens reported in this study were validated using ELISPOT and TCR sequencing in Reference 10.
- 11. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6(2), 80–92 (2012).
- 12. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 34(12), 1330–1338 (2016).
- 13. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinformatics 56, 15.9.1–15.9.17 (2016).
- 14. Allele-specific HLA Loss and immune escape in lung cancer evolution. Cell 171(6), 1259–1271.e11 (2017).
- 15. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10(8), e1003665 (2014).
- 16. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18(1), 248–262 (2017).
- 17. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127(8), 2930–2940 (2017).
- 18. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375(9), 819–829 (2016).
- 19. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7(2), 188–201 (2017).
- 20. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin. Cancer Res. 21(4), 712–720 (2015). •• JAK1 mutation was also found in this literature as a mechanism of ICI resistance.
- 21. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct. Target Ther. 6(1), 26 (2021). • Reported a total of 12 lung cancer patients treated with neoantigen dendritic cell vaccine.
